We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

PRI:NYSEPrimerica, Inc. Analysis

Data as of 2026-06-21 - not real-time

$281.78

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

Primerica (PRI) is trading at $281.78, well below its DCF‑derived fair value of $600 and the consensus 12‑month target of $300, indicating a material discount. The stock’s trailing P/E of 11.8 is notably lower than the industry average of 16.9, and the price‑to‑book of 3.5 suggests the market is not fully rewarding its $80.4 book value per share. Technicals reinforce the upside thesis: the 20‑day SMA (272.6) sits under the current price, the MACD histogram is positive (1.69) and the signal line is bullish, while the RSI at 59 shows room for further gains without being overbought. Volume is on an increasing trend and the fear‑greed index reads “Extreme Greed,” reflecting strong market appetite for the stock. The price is also comfortably above the 252.6 support level, giving a margin of safety on the downside.
On the fundamentals side, PRI delivered 8.1% revenue growth, a robust 71.5% gross margin and a 32.3% ROE, underscoring operational efficiency. Free cash flow of $1.07 bn comfortably covers the $4.48 dividend, yielding 1.59% with a modest 18% payout ratio, which supports dividend sustainability. The balance sheet is solid with a debt‑to‑equity of 74% and ample cash of $678 m, while beta under 0.4 signals low systematic risk. Overall volatility is elevated at 24.6% over 30 days, but the low beta and defensive insurance exposure keep the risk profile moderate. Given its stable cash generation and low correlation to broader market swings, the stock is well positioned for both income and capital appreciation. These combined factors make PRI an attractive undervalued, value‑oriented investment with upside potential across horizons.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Bullish MACD histogram and signal line
  • Price trading above key support with upside to resistance
  • Undervalued relative to DCF and industry peers

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong ROE and operating margins
  • Sustainable dividend with low payout ratio
  • Consensus 12‑month target price above current level

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • DCF fair value indicating >100% upside
  • Stable cash flow generation and low beta
  • Defensive insurance business serving middle‑income households

Key Metrics & Analysis

Financial Health

Revenue Growth8.10%
Profit Margin22.61%
P/E Ratio11.8
ROE32.34%
ROA4.63%
Debt/Equity73.79
P/B Ratio3.5
Op. Cash Flow$860.5M
Free Cash Flow$1.1B
Industry P/E16.9

Technical Analysis

TrendNeutral
RSI59.3
Support$252.63
Resistance$285.00
MA 20$272.64
MA 50$273.94
MA 200$264.40
MACDBullish
VolumeIncreasing
Fear & Greed Index91.46

Valuation

Fair Value$600.37
Target Price$298.50
Upside/Downside5.93%
GradeUndervalued
TypeValue
Dividend Yield1.59%

Risk Assessment

Beta0.40
Volatility24.63%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.